Publications
363 publications
- Date
- Relevance
-
GVS advice on the reassessment of tafamidis (Vyndaqel®)
The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...
-
Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)
The National Health Care Institute has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).
-
GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency
Zorginstituut Nederland recommends that ferrimaltol (Feraccru®) should not be included in the Medicine Reimbursement System ...
-
GVS advice on subcutaneous buprenorphine (Buvidal®)
Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...
-
Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)
The National Health Care Institute has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in ...
-
Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma
Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...
-
Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...
-
GVS advice for cladribine (Mavenclad®) – extension of further conditions
The National Health Care Institute has completed its reassessment whether the further conditions of cladribine (Mavenclad®) could ...
-
GVS assessment of calcifediol (Hidroferol®)
Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...
-
Package advice niraparib (Zejula®)
Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...